Predictors of early mortality after transcatheter aortic valve implantation

Didrik Kjønås,1 Gry Dahle,2 Henrik Schirmer,3,4 Siri Malm,5 Jo Eidet,6 Lars Aaberge,7 Terje Steigen,1,8 Svend Aakhus,9,10 Rolf Busund,8,11 Assami Rösner1

ABSTRACT

Objectives To investigate whether preoperative echocardiographic evaluation of ventricular function, especially right ventricular systolic and diastolic parameters including speckle-tracking analysis, could aid in the prediction of 30-day mortality after transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis.

Methods This is a prospective observational cohort study including 227 patients accepted for TAVI at the University Hospital of North Norway and Oslo University Hospital from February 2010 through June 2013. All patients underwent preoperative transthoracic echocardiography with retrospective speckle-tracking analysis. Primary endpoint was all-cause 30-day mortality.

Results All-cause 30-day mortality was 8.7% (n = 19). Independent predictors of 30-day mortality were systolic pulmonary arterial pressure (SPAP) > 60 mm Hg (HR: 7.7, 95% CI: 1.90 to 31.3), heart failure (HR: 2.9, 95% CI: 1.1 to 7.78), transapical access (HR: 3.8, 95% CI: 1.3 to 11.2), peripheral artery disease (HR: 6.0, 95% CI: 2.0 to 18.0) and body mass index (HR: 0.73, 95% CI: 0.61 to 0.87). C-statistic for the model generated was 0.91 (95% CI: 0.85 to 0.98). Besides elevated SPAP, no other echocardiographic measurements were found to be an independent predictor of early mortality.

Conclusion Except for elevated systolic pulmonary artery pressure, our data suggests that clinical rather than echocardiographic parameters are useful predictors of 30-day mortality after TAVI.

INTRODUCTION

Transcatheter aortic valve implantation (TAVI) has become a treatment option for a growing number of patients with aortic stenosis (AS) with intermediate to high risk for surgical aortic valve replacement (SAVR).1 However, there are still uncertainties about risk factors of early mortality for these patients. Identifying predictors of early mortality is important in order to improve patient selection and to give patients a better basis for informed consent. TAVI is now performed in patients with intermediate risk for SAVR2 and there are ongoing studies even in low-risk patients (NOTION-2/NCT02825134, PARTNER 3/NCT02675114, Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients/ NCT02701283). These patients are still candidates for open surgery where the risk factors are better identified and incorporated into validated risk algorithms. Despite the development of novel TAVI-specific risk algorithms,3–6 risk factors specific for TAVI are currently not fully understood. Both established surgical and novel TAVI-specific risk algorithms are comprised primarily of clinical parameters with the exception of systolic pulmonary arterial pressure (SPAP) and ejection fraction (EF). While the evaluation of left ventricular (LV) function on periprocedural outcome is still limited. LV dysfunction is linked to adverse outcome in several cardiovascular conditions including AS and heart failure.7 8 The aim of our study was to investigate whether preoperative echocardiographic evaluation of ventricular function, especially RV systolic and diastolic parameters including speckle-tracking analysis, in
addition to clinical parameters could aid in the prediction of unfavourable early outcome after TAVI.

METHODS
Study population
From February 2010 through June 2013, 227 patients from the University Hospital of North Norway Tromsø and Oslo University Hospital Rikshospitalet with severe symptomatic AS accepted for TAVI were included in the study. A multidisciplinary heart team determined the patient suitability for TAVI considering cognitive function and comorbid status of the patient as well as technical feasibility. Patients with inability to give informed consent, life expectancy less than 12 months and low motivation for treatment were not offered TAVI. Primary endpoint was all-cause 30-day mortality classified according to the Valve Academic Research Consortium (VARC)-2 criteria. The study was approved by the Regional Ethical Committees for Medical Research Ethics, North and South East Norway. All patients gave written informed consent.

Patient characteristics
Patient demographics, clinical characteristics, periprocedural mortality and complications were obtained from the patients’ electronic records. Chronic obstructive pulmonary disease (COPD) was classified according to the global initiative for chronic obstructive lung disease (GOLD) classification. Patients with COPD of unknown grade were classified as having grade 1. Previous cerebrovascular events comprised both previous strokes and transient ischaemic attacks. Chronic and paroxysmal atrial fibrillation/flutter was grouped as one variable. Heart failure was defined as physician-documented clinical signs of heart failure in the form of unusual dyspnoea on light exertion, orthopnoea, fluid retention, rales on auscultation or pulmonary oedema on chest X-ray less than 2 weeks prior to TAVI. Periperal artery disease (PAD) was defined as claudication, previous amputation due to vascular insufficiency, previous reconstructive surgery or percutaneous intervention, abdominal aortic aneurism and/or >50% stenosis in a peripheral artery diagnosed by CT or angiographic imaging.

Echocardiography
All patients underwent preoperative transthoracic echocardiographic evaluation with either an iE33 (S5-1 probe, Philips Medical systems, Andover, MA) or a Vivid E9 (GE Vingmed, Horten, Norway) scanner using a 2.5–3.5 MHz transducer in the left lateral decubital position. Conventional two-dimensional grey-scale images were obtained in the parasternal long-axis and short-axis view, as well as the apical four-chamber, two-chamber and three-chamber views. Left ventricular EF (LVEF) was derived from the Simpson’s biplane method. The same two views served to calculate left atrial volumes at end-systole. LV longitudinal function was assessed by mitral annular plane systolic excursion in the septal and lateral mitral ring in the apical four-chamber view. Intraocular septum thickness in diastole was measured in M-mode images in the parasternal long-axis view. Diastolic LV function was assessed by E/A ratio, E/e’ ratio and E deceleration time. The degree of AS was derived from the mean and peak gradient of the Doppler flow across the aortic valve, as well as the aortic valve area derived by the continuity equation. LV stroke volume, cardiac output and cardiac index were derived from the LV outflow tract (LVOT) diameter and LVOT velocity time integral. The degree of aortic regurgitation was estimated by the size of the regurgitation area by colour Doppler, pressure half-time and diastolic velocities in descending aorta by Doppler-flow signal. The degree of mitral regurgitation (MR) was based on measurement and visual assessment of colour Doppler images, vena contracta and proximal isovelocity surface area.

RV geometry and function were evaluated in an adjusted four-chamber view at the largest transversal diameter of the RV. Systolic RV function was assessed by tricuspid annular peak systolic excursion (TAPSE) and tissue velocity imaging derived tricuspid annular systolic velocity in the basal RV free wall. RV areas were measured in end-diastole and end-systole and used for calculating fractional area change. RV longitudinal diameter in diastole was measured as the distance from the RV apex to the middle of the RV annulus. RV mediolateral diameter in diastole was measured from the intraventricular septum to the RV free wall at the widest part of the RV cavity. SPAP was derived from continuous wave Doppler measurements of tricuspid regurgitation (TR) and respiratory variation of the diameter of the inferior vena cava. When TR gradient was not recorded, SPAP was considered being <30 mm Hg if TR was described by visual assessment as trivial or mild, and 30–60 mm Hg when TR was described as moderate.

Strain analyses
Strain analyses were performed using speckle-tracking software VVI7 (Siemens, Mountain View, CA, USA). Longitudinal LV strain was obtained by analyses of the LV in the apical four-chamber, two-chamber and three-chamber views. Longitudinal RV strain was obtained from an apical four-chamber view including segments of the lateral wall only (figure 1). The time point of the aortic valve closure was measured in continuous Doppler registrations of the aortic flow. Global strain peak longitudinal strain values were extracted from strain curves by defining the systolic time interval between R-wave and the time point of aortic valve closure. Strain curves with artefacts due to reverberation, air artefact or insufficient tracking were discarded based on subjective visual assessment. In patients with atrial arrhythmia, strain from three cycles, if available, was obtained and averaged.

TAVI procedure
All TAVI procedures were performed under general anaesthesia with transfemoral (TF), transaortic (TAo) or transapical (TA) access using either first-generation
Valvular heart disease

Figure 1  Example of how the RV strain curves are generated from a two-dimensional four-chamber view. RV, right ventricular.

The patients’ demographics, clinical characteristics and periprocedural results are listed in table 1 and echocardiographic parameters in table 2. Nine patients were excluded from final analysis including three patients who did not undergo TAVI, five cases where preoperative echocardiographic images were not accessible and one patient with aortic insufficiency and not stenosis. The remaining 218 patients were included in the final analysis. All-cause mortality at 30 days was 8.7% (n=19). Six (32%) of these patients died peroperatively. Postoperatively, 12 (63%) died of cardiovascular causes where three (16%) were due to myocardial infarction, five (26%) secondary to cerebrovascular event and one (5%) from either bleeding, worsening heart failure, procedure related or death of unknown cause. One (5%) died of non-cardiovascular cause due to subarachnoid haemorrhage secondary to trauma. These patients had significantly lower body mass index (BMI), higher peripheral vascular disease burden, more TA procedures and a higher percentage of patients with SPAP >60 mm Hg. The difference in the presence of moderate to severe MR and heart failure was borderline significant between the groups. There was no interaction between variables in our data consequently a forward multivariable regression analysis was performed. All clinically significant variables with p<0.15 in univariable analysis and the result of multivariable analysis are shown in table 3. All variables included in the final model were highly significant in univariable analysis and maintained significance after multivariable analysis. Figure 2 displays the Kaplan-Meier curves for each independent predictor of all-cause 30-day mortality.

Reproducibility
To determine the interobserver and intraobserver variability of longitudinal strain measurements, recordings from 30 patients were selected at random and another experienced observer repeated the analysis. The same data were reanalysed by the main observer after several months. Intraclass correlation coefficient was used to test interobserver and intra-observer variability.

RESULTS
The self-expanding Medtronic CoreValve (Medtronic, Minneapolis, MN, USA) or either first- or second-generation Edwards SAPIEN-SAPIEN XT balloon-expandable valve (Edwards Lifesciences, Irvine, CA, USA). Valve size was determined from the aortic annular diameter measured by CT scan reconstruction and/or transesophageal echocardiography. TF access was the preferred modality. TA access was used in the presence of highly calcified and tortuous pelvic vessels given acceptable LV and respiratory function. In the presence of inaccessible peripheral vessels and reduced LVEF or COPD, TAo access was used.

Statistical analysis
The power of the study was calculated using the power calculation package in STATA V.12. We estimated a minimum detectable HR of 1.25 for mortality for a 1-unit change for each echocardiographic variable with a power of 80% with a 5% probability of a false-negative result. Data are presented as number (%) or mean±SD as appropriate. Variables between groups were compared using Pearson χ² or independent t-test for percentages and continuous variables, respectively. Univariable Cox regression analysis was performed for all-cause 30-day mortality. Variables with p<0.15 and deemed clinically relevant were selected and tested for interaction and co-linearity prior to forward and backward multivariable Cox regression analysis. When the interaction terms in the backwards analysis were non-significant, the forward model was used. No imputation for missing data was performed and multivariable analyses performed on all available patients for each analysis. The final model was based on 213 patients. P<0.05 in multivariable analysis was considered significant. C-statistic for predicted 30-day mortality in our cohort was obtained from receiver operating characteristic (ROC) analyses of the predicted probabilities generated from binary logistic regression. All statistical analysis was done using SPSS V.24 (SPSS, Chicago, IL, USA).

Figure 2  Kaplan-Meier curves for each independent predictor of all-cause 30-day mortality.
Table 1  Baseline demographics, clinical characteristics and periprocedural results stratified according to 30-day mortality

| Variable                              | Survivors (n=199) | Dead (n=19) | P value |
|---------------------------------------|-------------------|-------------|---------|
| Age, years                            | 82±7              | 80±8        | 0.330   |
| Female                                | 89(45)            | 9 (47)      | 0.825   |
| Body surface area, m²                  | 1.8±0.2           | 1.7±0.1     | 0.005   |
| Body mass index, kg/m²                 | 26±5              | 22±3        | 0.001   |
| STS score                             | 5.9±3.9           | 8.3±4.4     | 0.012   |
| Euroscore                              | 9.4±7.2           | 11.3±8.8    | 0.300   |
| NYHA class                             |                   |             | 0.527   |
| II                                     | 29(15)            | 2 (11)      |         |
| III                                    | 120(60)           | 10(53)      |         |
| IV                                     | 50(25)            | 7 (37)      |         |
| Heart failure                          | 84(42)            | 12(63)      | 0.079   |
| Hypertension                           | 133(67)           | 15(79)      | 0.280   |
| Atrial dysrhythm                       | 89(45)            | 11(58)      | 0.271   |
| Previous myocardial infarction         | 76(38)            | 6 (32)      | 0.570   |
| Previous PCI                           | 78(39)            | 9 (47)      | 0.487   |
| Previous cardiac surgery               | 93(47)            | 5 (26)      | 0.087   |
| LBBB                                   | 18(9)             | 2 (11)      | 0.831   |
| Peripheral artery disease              | 66(33)            | 14(74)      | <0.000  |
| Porcelain aorta                        | 21(11)            | 5 (26)      | 0.043   |
| Cerebrovascular disease                | 52(26)            | 6 (32)      | 0.608   |
| Previous cerebrovascular event         | 46(23)            | 6 (32)      | 0.408   |
| Immune compromised                     | 24(12)            | 4 (21)      | 0.263   |
| Diabetes                               | 59(30)            | 3 (1.5)     | 0.201   |
| COPD                                   | 70(35)            | 8 (42)      | 0.547   |
| eGFR, ml/min/1.73 m²                   | 54±20             | 50±24       | 0.055   |
| Previous radiation therapy             | 8 (4)             | 1 (5)       | 0.795   |
| Access                                 |                   |             | 0.001   |
| Transfemoral                           | 117(59)           | 5 (26)      |         |
| Transaortic                            | 27(14)            | 1 (5)       |         |
| Transapical                            | 55(28)            | 13(68)      |         |
| Valve type                             |                   |             | 0.206   |
| Edwards Sapien                         | 153(77)           | 17(89)      |         |
| CoreValve                              | 46(23)            | 2 (11)      |         |
| Periprocedural results                 |                   |             |         |
| Intraoperative mortality               | –                 | 6 (2.8)     |         |
| Myocardial infarction                  | 3 (1.5)           | 3 (16)      | <0.000  |
| Cerebrovascular event                  | 6 (3)             | 7 (37)      | <0.000  |
| Major or life-threatening bleeding      | 5 (2.5)           | 5 (26)      | <0.000  |
| PVL moderate to severe                 | 18(9)             | 2 (10.5)    | 0.085   |

Table 1  Continued

| Variable                              | Survivors (n=199) | Dead (n=19) | P value |
|---------------------------------------|-------------------|-------------|---------|
| Permanent PM postoperatively           | 17 (8.5)          | 0 (0)       | –       |

Values are mean±SD or n (%)

COPD, chronic obstructive pulmonary disease; LBBB, left bundle branch block; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PM, pacemaker; PVL, paravalvular leakage; STS, society of thoracic surgeons; eGFR, estimated glomerular filtration rate; eGFR, estimated glomerular filtration rate.

SPAP >60 mm Hg was the only independent echocardiographic predictor of early mortality and was present in 21 (9.6%) of the patients. In all, 14 (67%) of these had clinical signs of heart failure prior to surgery, 11 (52%) had COPD and 6 (29%) had both. Out of the 21 patients with SPAP >60 mm Hg, five (24%) died within 30 days after treatment, with three having concomitant clinical signs of heart failure, two had COPD and one had both. Heart failure was present in 12 (63%) patients with early mortality compared with 96 (44%) in the whole cohort. Neither New York Heart Association (NYHA) IV nor NYHA III and IV combined were identified as risk factors by univariable analysis. TA access with concomitant PAD was present in 12 (63%) patients who died within 30 days compared with 22 (11%) of the survivors. All of these patients died of cardiovascular causes. BMI was analysed as a continuous variable and was still statistically significant as a predictor of early mortality even when patients with BMI <20 kg/m² (n=17) were excluded from analyses (HR: 0.79, 95% CI: 0.649 to 0.97, p=0.025). C-statistic for the model generated from multivariable regression analysis in our cohort was 0.91 (95% CI: 0.85 to 0.98).

Reproducibility

Intraclass correlation coefficient for longitudinal strain measurement was 0.799 (95% CI 0.695 to 0.868) and 0.924 (95% CI 0.885 to 0.950) for interobserver and intraobserver variability, respectively.

**DISCUSSION**

All-cause 30-day mortality rate was 8.7% which is similar to registry data from the same period. All but one patient died of cardiovascular causes as defined by the VARG-2 criteria. In our study, we identified SPAP >60 mm Hg, heart failure, TA access, PAD and BMI as independent predictors of 30-day mortality after TAVI and the model showed high accuracy in ROC analysis correctly allocating 91% as cases or controls.

Despite a thorough preoperative echocardiographic evaluation, especially of RV systolic and diastolic functional parameters, we did not identify any echocardiographic marker for early mortality except for SPAP >60 mm Hg.
### Table 2 Preoperative echocardiographic parameters stratified according to 30-day mortality

| Variable* | Survivors (n=199) | Dead (n=19) | P value |
|-----------|------------------|-------------|---------|
| LVEF % (n=212) | ≥50 100(50) 10(53) | 0.751 |
| 31–49 | 72(36) 7 (37) | 0.844 |
| ≤30 | 22(11) 1 (5) | 0.159 |
| LVLS, (n=198) | −11.1±3.8 −10.9±3.6 | 0.783 |
| MAPSE septal, cm (n=212) | 0.70±0.27 0.67±0.31 | 0.691 |
| MAPSE lateral, cm (n=212) | 0.99±0.32 1.0±0.31 | 0.844 |
| IVSDd, cm (n=202) | 1.2±0.3 1.3±0.3 | 0.158 |
| AVA, cm² (n=215) | 0.63±0.21 0.58±0.20 | 0.407 |
| AVA index, cm²/m² (n=215) | 0.34±0.11 0.34±0.11 | 0.802 |
| AV gradient max, mm Hg (n=215) | 84±24 77±20 | 0.189 |
| AV gradient mean, mm Hg (n=215) | 52±15 47±12 | 0.202 |
| AV max velocity, m/s (n=216) | 453±67 430±58 | 0.162 |
| SV LVOT index, ml/m² (n=216) | 37±11 35±12 | 0.559 |
| LVOT diameter, cm (n=216) | 2.1±0.25 2.1±0.23 | 0.348 |
| E/e (n=148) | 19.2±8.1 18.1±9.7 | 0.644 |
| E/A (n=147) | 1.1±0.6 0.8±0.5 | 0.159 |
| MV deceleration time, ms (n=215) | 227±92 221±89 | 0.769 |
| MV E, cm/s (n=215) | 96±34 89±39 | 0.454 |
| LA volume index, mL/m² (n=204) | 53±20 53±22 | 0.995 |
| MR moderate to severe (n=209) | 38(20) 7 (37) | 0.079 |
| AR moderate to severe (n=213) | 35(18) 3 (16) | 0.777 |
| Mitral stenosis | 9 (5) 1 (5) | 0.816 |
| SPAP, mm Hg (n=215) | >60 16(8) 5 (26) | 0.033 |
| 30–60 | 120(60) 10(53) | 0.140 |
| <30 | 63(32) 4 (21) | 0.469 |
| TAPSE, cm (n=204) | 1.6±0.5 1.7±0.5 | 0.405 |
| TASSV, cm/s (n=133) | 9.5±3.2 10.9±3.3 | 0.140 |
| FAC, % (n=197) | 36±13 37±9 | 0.655 |
| RVEDA, cm² (n=197) | 20±5 21±5 | 0.872 |
| RVEF, % (n=197) | 13±5 13±3 | 0.562 |
| TR moderate to severe (n=213) | 40(21) 5 (26) | 0.888 |

In a study based on 870 patients undergoing TAVI, Testa et al found that patients with TAPSE <10 mm had increased risk of mortality at 30 days in contrast to two other studies where TAPSE was not found to predict early mortality. Both RV dilation and reduced TAPSE have been linked to increased risk of long-term mortality. Barvalia et al found TR to be an independent risk factor for early mortality after TAVI. To the best of our knowledge, no other studies have identified any RV ventricular functional parameter as independent risk factor for early mortality besides elevated SPAP. The number of previous studies evaluating the effects of RV function on periprocedural outcome is low and the RV functional parameters included are often incomplete. Based on our results, the addition of speckle-tracking analysis did not yield any additional benefit in terms of evaluating the effect of RV nor LV function on early mortality.

### Pulmonary hypertension

In all patients with pulmonary hypertension (PHT) in our cohort, we observed the two most common reasons for this condition; either COPD, heart failure or both. COPD has been identified as an important comorbid factor in patients undergoing TAVI with PHT. In contrast to large registry studies, we did not identify COPD as an independent predictor for early mortality. While mild PHT might be associated with reversible increased PAP in heart failure, markedly elevated PAP probably indicates an irreversible condition in patients with heart failure that might not improve after TAVI. Irreversible PHT causes reduced cardio-circulatory reserve resulting in impaired ability to increase stroke volume and cardiac output. As a consequence, patients undergoing TAVI might have inadequate circulatory compensatory mechanism during and after the intervention in response to rapid load changes, anaesthesia and rapid pacing. Our finding of marked PHT as an independent risk factor for early mortality after TAVI is in accordance with data from several registry studies.
Table 3  Results of univariable and multivariable analysis for all-cause 30-day mortality

| Variable                  | Univariable | Multivariable |
|---------------------------|-------------|---------------|
|                           | P value     | HR            | 95% CI      | P value     | HR            | 95% CI      |
| Body mass index, kg/m²    | <0.000      | 0.78          | 0.68 to 0.90| <0.000      | 0.73          | 0.61 to 0.87 |
| Heart failure             | 0.083       | 2.78          | 0.90 to 5.80| 0.03        | 2.95          | 1.11 to 7.78 |
| Access                    | 0.004       |               |             | 0.017       |               |             |
| Transfemoral              | Ref         |               |             | Ref         |               |             |
| Transaortic               | 0.905       | 0.88          | 0.10 to 7.51| 0.614       | 0.57          | 0.06 to 5.14 |
| Transapical               | 0.011       | 4.98          | 1.78 to 13.99| 0.015       | 3.8           | 1.29 to 11.16|
| SPAP, mm Hg               | 0.053       |               |             | 0.004       |               |             |
| <30                       | Ref         |               |             | Ref         |               |             |
| 30–60                     | 0.737       | 1.22          | 0.38 to 3.89| 0.688       | 1.28          | 0.39 to 4.14 |
| >60                       | 0.038       | 4.03          | 1.08 to 14.99| 0.004       | 7.77          | 1.90 to 31.28|
| Peripheral artery disease | 0.002       | 5.16          | 1.86 to 14.34| 0.002       | 5.95          | 1.97 to 17.99|
| MR moderate to severe     | 0.091       | 2.24          | 0.88 to 5.68| NS          | –             | –           |
| COPD                      | 0.065       | 1.40          | 1.01 to 7.79| NS          | –             | –           |
| Previous cardiac surgery  | 0.101       | 0.43          | 0.15 to 1.18| NS          | –             | –           |
| eGFR ml/min/1.73 m²       | 0.055       | 0.98          | 0.96 to 1.00| NS          | –             | –           |
| Porcelain aorta           | 0.048       | 2.81          | 1.01 to 7.79| NS          | –             | –           |

COPD, chronic obstructive pulmonary disease; MR, mitral regurgitation; NS, non-significant; SPAP, systolic pulmonary arterial pressure; eGFR, estimated glomerular filtration rate.

Heart failure
Clinical signs of heart failure within 2 weeks prior to TAVI was an independent predictor of early mortality in our cohort. Opposed to physical and radiological signs of heart failure, the NYHA classification is based on limitations on physical activity. The majority of our patients were classified as NYHA III-IV. The distinction between classes III and IV is subjective and might in addition to cardiac have its origin in respiratory, musculoskeletal and mental causes, or a combination of these factors. This might suggest that in this setting objective clinical signs of heart failure could be more helpful than only functional limitation when evaluating symptom severity. Furthermore, it may also indicate that optimisation of medical heart failure treatment prior to surgery might be a key factor to improve outcome.

Access and PAD
Central access, especially TA access, has emerged as a significant risk factor for early mortality compared with TF access. Compared with patients receiving TF-TAVI, these patients have a higher burden of comorbidities and higher preoperative risk based on preoperative surgical risk algorithms. Central access is also more invasive and requires surgical access via a limited thoracotomy or sternotomy, which might impair postoperative respiratory effort secondary to pain. Our cohort had a low number of patients treated with TAo access, rendering to low power to assess if it is a significant risk factor. TF access depends on anatomical accessibility and adequate diameter of femoral and iliac vessels to facilitate instrumentation of introducer sheaths, but the presence of PAD does not necessarily result in a central access. If there are adequate diameter of access site vessels and satisfactory vascular anatomy proximally, TF access can be employed. Despite patients treated with central access having a higher burden of comorbidities, including PAD that might impact choice of access site, our data suggest that access and PAD are independent risk factors for early mortality. This might be due to factors related to the procedure itself, a consequence of patient selection or both. Whatever the reason, choice of access site is an important factor in risk evaluation when considering patients for TAVI as it seems to convey increased risk in itself. In addition to being a factor in the selection of access site, PAD reflects the patients’ vascular disease burden and has been shown to increase the risk of TF-TAVI vascular complications, which, in turn, has been associated with increased 30-day mortality. A meta-analysis by D’Ascenzo et al showed that the extent of coronary artery disease and the results of percutaneous coronary intervention (PCI), evaluated by Syntax Score and residual Syntax Score, respectively, were predictive of 1-year but not 30-day mortality. Despite not calculating Syntax Score in our cohort, we found neither PCI nor previous myocardial infarction to be predictive of 30-day mortality. Although all patients in our cohort underwent TAVI under general anaesthesia, TF-TAVI is at present often...
BMI might be a possible surrogate for frailty when patients with low BMI have a higher mortality compared with patients with high BMI. This finding is consistent with previous studies showing a lower incidence of cardiac complications and death in patients with high BMI (obesity paradox) [11]. However, the risk factors not captured by traditional surgical risk criteria were rather strict and patients with lower preoperative risk are now offered TAVI, which may alter the risk considerably. Our univariable regression analysis resulted in several significant variables with the risk of low power in a relatively small cohort. This in general could be viewed as a limitation. However, since a forward multivariable regression analysis was performed and all variables were highly significant, stricter inclusion criteria would not have changed the final model.

CONCLUSION

With the exception of elevated SPAP, our data suggest that clinical rather than echocardiographic parameters are more useful as predictors of 30-day mortality after TAVI. We identified SPAP >60 mm Hg, heart failure, TA access, PAD and BMI as independent predictors of 30-day mortality after TAVI. Our data suggest that these factors should be taken into consideration when evaluating high-risk patients for TAVI.

Author affiliations
1Department of Cardiology, University Hospital of North Norway, Tromsø, Norway
2Department of Cardiology, Akershus University Hospital, Lørenskog, Norway
3Department of Cardiology, University Hospital of North Norway, Tromsø, Norway
4Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
5Department of Cardiology, University Hospital of North Norway, Harstad, Norway
6Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
7Department of Cardiology, Akershus University Hospital, Lørenskog, Norway
8Institute of Clinical Medicine, The Arctic University of Norway, UiT, Tromsø, Norway
9Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
10Department of Cardiology, Akershus University Hospital, Lørenskog, Norway
11Department of Cardiology and Vascular Surgery, Universitetssykehuset Nord-Norge, Tromso, Norway

Contributors AR, HS, RB and SA designed the protocol. AR, SA, GD, JE, SM, LA and RB collected the data. DK performed the data extraction and the offline calculations. DK did the statistical analysis and drafting of the first version of the manuscript in close cooperation with AR, HS, RB and SA. All authors contributed to the revision and all aspects of the final manuscript, and are guarantors of the study.

Funding DK received grant from the Regional Health Authorities of North Norway.

Competing interests Rolf Busund is a consultant for Edwards Lifesciences and has received speakers fee from Abbott. Lars Aaberge is a proctor for Edwards Lifesciences.

Patient consent for publication Obtained.

Ethics approval Regional Ethical Committees for Medical Research Ethics, North and South East Norway.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are available upon reasonable request.

Figure 2 Kaplan-Meier curves for each independent predictor stratified according to 30-day all-cause mortality. Heart failure defined as clinical signs of heart failure in the form of unusual dyspnoea on light exertion, orthopnoea, fluid retention, rales on auscultation, or pulmonary oedema on chest X-ray less than 2 weeks prior to TAVI. BMI, body mass index; eGFR, estimated glomerular filtration rate; PAD, peripheral artery disease; SPAP, systolic pulmonary arterial pressure; TAVI, transcatheter aortic valve implantation, done in local anaesthesia and sedation, which has been shown to reduce 30-day mortality after TAVI. Although TA-TAVI being a valid option in clinical practice when TF access is not technically feasible, TF-TAVI should be considered the preferred modality.

BMI

The term ‘obesity paradox’ was first used to describe the increased early mortality after PCI in patients with low BMI and has also been observed in patients treated with TAVI. The VAREC-2 consensus document states that frailty, where BMI<20 kg/m² is a component, is among the risk factors not captured by traditional surgical risk scores. BMI might be a possible surrogate for frailty or cardiac cachexia in the TAVI population, but there are conflicting data whether low BMI confers risk in itself compared with the apparently protective effect of obesity. In our cohort, BMI was analysed as a continuous variable and was still statistically significant even when patients with low BMI (<20 kg/m²) were excluded. Although we had few patients that were morbidly obese, our data suggest better survival with increasing BMI supporting the obesity paradox.

Kjønås D, et al. Open Heart 2019;6:e000936. doi:10.1136/openhrt-2018-000936

Valvular heart disease

Compared with large registry studies, our study included patients from only two centres and was performed during an early stage after the implementation of TAVI as a treatment option. This makes our findings less generalisable at present, and the results may be affected by center-and operator experience in addition to improvements in operative technique and equipment. Our inclusion criteria were rather strict and patients with lower preoperative risk are now offered TAVI, which may alter the risk considerably. Our univariable regression analysis resulted in several significant variables with the risk of low power in a relatively small cohort. This in general could be viewed as a limitation. However, since a forward multivariable regression analysis was performed and all variables were highly significant, stricter inclusion criteria would not have changed the final model.

CONCLUSION

With the exception of elevated SPAP, our data suggest that clinical rather than echocardiographic parameters are more useful as predictors of 30-day mortality after TAVI. We identified SPAP >60 mm Hg, heart failure, TA access, PAD and BMI as independent predictors of 30-day mortality after TAVI. Our data suggest that these factors should be taken into consideration when evaluating high-risk patients for TAVI.

Author affiliations
1Department of Cardiology, University Hospital of North Norway, Tromsø, Norway
2Department of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway
3Department of Cardiology, Akershus University Hospital, Lørenskog, Norway
4Institute of Clinical Medicine, University of Oslo
5Department of Cardiology, University Hospital of North Norway, Harstad, Norway
6Department of Anaesthesiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
7Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
8Institute of Clinical Medicine, The Arctic University of Norway, UiT, Tromsø, Norway
9Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
10Department of Cardiology, Akershus University Hospital, Lørenskog, Norway
11Department of Cardiology, Saint Olav University Hospital, Trondheim, Norway
12Department of Cardiology and Vascular Surgery, Universitetssykehuset Nord-Norge, Tromso, Norway

Contributors AR, HS, RB and SA designed the protocol. AR, SA, GD, JE, SM, LA and RB collected the data. DK performed the data extraction and the offline calculations. DK did the statistical analysis and drafting of the first version of the manuscript in close cooperation with AR, HS, RB and SA. All authors contributed to the revision and all aspects of the final manuscript, and are guarantors of the study.

Funding DK received grant from the Regional Health Authorities of North Norway.

Competing interests Rolf Busund is a consultant for Edwards Lifesciences and has received speakers fee from Abbott. Lars Aaberge is a proctor for Edwards Lifesciences.

Patient consent for publication Obtained.

Ethics approval Regional Ethical Committees for Medical Research Ethics, North and South East Norway.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are available upon reasonable request.
REFERENCES
1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;363:1597–607.
2. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 2016;374:1693–701.
3. Capodanno D, Barbanti M, Tamburino C, et al. A simple risk Tool (the OBSERVANT Score) for prediction of 30-day mortality after transcatheter aortic valve replacement. *Am J Cardiol* 2014;113:1851–8.
4. Iung B, Lefaucheur J, Verdecchia P, et al. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. *Heart* 2014;100:1016–23.
5. Kötting J, Schiller W, Beckmann A, et al. German aortic valve score: a new scoring system for prediction of mortality related to aortic valve procedures in adults. *Eur J Cardiothorac Surg* 2013;43:971–7.
6. Haikin A, Steinvil A, Witberg G, et al. Mortality prediction following transcatheter aortic valve replacement: a quantitative comparison of risk scores derived from populations treated with either surgical or percutaneous aortic valve replacement. The Israel TAVR registry risk model accuracy assessment (HARRMA) study. *Int J Cardiol* 2016;215:227–31.
7. Schaefer U, Zahn R, Abdel-Wahab M, et al. Comparison of outcomes of patients with left ventricular ejection fractions ≥30% versus <30% having transcatheter aortic valve implantation (from the German Transcatheter Aortic Valve Interventions Registry). *Am J Cardiol* 2015;115:656–63.
8. Ferrante G, Presbitero P, Pagnotta P, et al. Impact of severe left ventricular dysfunction on mid-term mortality in elderly patients undergoing transcatheter aortic valve implantation. *J Geriatr Cardiol* 2016;13:290–8.
9. Galli E, Gueritte Y, Feneon D, et al. Prevalence and prognostic value of right ventricular dysfunction in severe aortic stenosis. *European Heart Journal - Cardiovascular Imaging* 2015;16:531–8.
10. Kjaergaard J, Akin D, Iversen KK, et al. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. *Eur J Heart Fail* 2007;9:610–6.
11. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document. *J Am Coll Cardiol* 2012;60:1438–54.
12. Mack MJ, Brennan JM, Brindis R, et al. Outcomes following transcatheter aortic valve replacement in the United States. *JAMA* 2013;310:2069–77.
13. Testa L, Latib A, De Marco F, et al. The failing right heart: implications and evolution in high-risk patients undergoing transcatheter aortic valve implantation. *EuroIntervention* 2016;12:1542–9.
14. Giessi DP, Kerber S, Barth S, et al. Impact of right and left ventricular systolic dysfunction on perioperative outcome and long-term survival after transcatheter aortic valve replacement. *J Interv Cardiol* 2017;30:217–25.
15. Poliacikova P, Cockburn J, Pareek N, et al. Prognostic impact of pre-existing right ventricular dysfunction on the outcome of transcatheter aortic valve implantation. *J Invasive Cardiol* 2013;25:142–5.
16. Schwartz LA, Rosenbaum Z, Ghantous E, et al. Impact of right ventricular dysfunction and tricuspid regurgitation on outcomes in patients undergoing transcatheter aortic valve replacement. *J Am Soc Echocardiogr* 2017;30:36–46.
17. Ito S, Pislaru SV, Soo WM, et al. Impact of right ventricular size and function on survival following transcatheter aortic valve replacement. *Int J Cardiol* 2016;221:269–74.
18. Barvalia M, Tayal R, Cohen M, et al. Impact of tricuspid valve regurgitation on early outcomes after transcatheter aortic valve replacement. *J Heart Valve Dis* 2017;26:380–5.
19. Oudiz RJ, Pulvirenti RA. Hypertension associated with left-sided heart disease. *Clin Chest Med* 2007;28:233–41.
20. Ghatak A, Bavishi C, Cardoso RN, et al. Complications and Mortality In Patients Undergoing Transcatheter Aortic Valve Replacement With Edwards SAPIEN & SAPIEN XT Valves: A Meta-Analysis of World-Wide Studies and Registries Comparing the Transapical and Transfemoral Accesses. *J Interv Cardiol* 2015;28:266–78.
21. Panchal HB, Ladia V, Desai S, et al. A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis. *Am J Cardiol* 2013;112:850–60.
22. Kolfman E, Magalhaes M, Kiramiyian S, et al. Impact of transfemoral versus transapical access on mortality among patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. *Cardiovac Revasc Med* 2016;17:318–21.
23. Toggweiler S, Gurvitch R, Leipsic J, et al. Percutaneous aortic valve replacement. *J Am Coll Cardiol* 2012;59:113–8.
24. Hayashiya K, Ielasi L, Old T, et al. Transcatheter aortic valve implantation. *JACC Cardiovasc Interv* 2011;4:851–8.
25. Moretti C, D’Amico M, D’Ascenzo F, et al. Impact on prognosis of periprocedural bleeding after TAVI: mid-term follow-up of a multicenter prospective study. *J Interv Cardiol* 2014;27:293–9.
26. D’Ascenzo F, Verzini R, Vercioni M, et al. Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results. *EuroIntervention* 2018;14:e1198–7.
27. Villabilanca PA, Mohananey D, Nikolic K, et al. Comparison of local versus general anesthesia in patients undergoing transcatheter aortic valve replacement: a meta-analysis. *Catheter Cardiovasc Interv* 2018;91:330–42.
28. Ellis SG, Elliott J, Horrigan M, et al. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. *Am J Cardiol* 1996;78:642–6.
29. van der Boon RMA, Chiefi F, Dumontel N, et al. Effect of body mass index on short- and long-term outcomes after transcatheter aortic valve implantation. *Am J Cardiol* 2013;111:231–6.
30. Yamamoto M, Mouillet G, Oguri A, et al. Effect of body mass index on 30- and 365-day complication and survival rates of transcatheter aortic valve implantation (from the FrEnch Aortic National CoreValve and Edwards 2 [FRANCE 2] registry). *Am J Cardiol* 2013;112:1932–7.
31. ALICE (All-Literature Investigation of Cardiovascular Evidence) Group, Takagi H, Uemoto T. "Obesity paradox" in transcatheter aortic valve implantation. *J Cardiovasc Surg* 2017;58:113–20.
32. Yamamoto M, Hayashida K, Watanabe Y, et al. Effect of body mass index ≤20 kg/m2 on events in patients who underwent transcatheter aortic valve replacement. *Am J Cardiol* 2015;115:227–33.
33. Kolfman E, Kiramiyian S, Negi S, et al. Body mass index association with survival in severe aortic stenosis patients undergoing transcatheter aortic valve replacement. *Catheter Cardiovasc Interv* 2016;88:118–24.